Core Viewpoint - The approval of the new generation continuous glucose monitoring system, Silicore Dynamic GS3, by the NMPA marks a significant development for domestic medical device companies, allowing them to compete in a market traditionally dominated by multinational corporations [2][3]. Market Overview - The CGM market is experiencing rapid growth, with the market size in China projected to reach approximately 1.54 billion yuan in 2025, reflecting a year-on-year increase of 45.8%, significantly outpacing the traditional blood glucose meter market, which grows at about 10% [9]. - Factors driving this growth include an increasing number of diabetes patients, greater acceptance of continuous glucose monitoring by hospitals, expanded use of insulin pumps and closed-loop systems, and rising demand for home-based chronic disease management [12]. Technological Competition - The core of CGM technology competition lies in the sensor materials and algorithm models, which form the main technical barriers. The sensors must maintain stable glucose detection accuracy while operating subcutaneously for several days [4][6]. - The Silicore Dynamic GS3 has achieved key performance indicators that meet the international iCGM standards, which are typically used for continuous glucose monitoring devices linked with insulin pumps or automated insulin delivery systems [6]. Company Background - Silicore Bionic, established in 2015 and headquartered in Shenzhen, China, focuses on the research and production of continuous glucose monitoring technology. Its main products include the Silicore Dynamic series for continuous blood glucose monitoring and management [11]. - As of the end of 2025, the company has over 3 million cumulative users across more than 100 countries and regions, and it has initiated the IPO process [11]. Opportunities and Challenges for Domestic Manufacturers - Domestic CGM companies, including Silicore Bionic, face challenges such as the need for clinical data accumulation, as international competitors often have over a decade of clinical application data [15]. - Brand trust and distribution channels remain critical, as hospitals and patients tend to favor established brands. Additionally, the future competition will not only focus on sensors but also on the integration of insulin pumps, digital platforms, and closed-loop systems [16].

Financial Data and Key Metrics Changes - For Q4 2025, the company reported worldwide revenue of $1.26 billion, a 13% increase from $1.11 billion in Q4 2024, with organic growth at 12% [15][16] - U.S. revenue reached $892 million in Q4 2025, up 11% from $803 million in Q4 2024 [15] - International revenue grew 18% to $368 million in Q4 2025, with organic growth at 15% [16] - Gross profit for Q4 was $799.8 million, representing 63.5% of revenue, an increase from 59.4% in Q4 2024 [17] - Operating income was $331.5 million, or 26.3% of revenue, compared to $209.5 million, or 18.8% of revenue, in Q4 2024 [18] - Net income for Q4 was $265.1 million, equating to $0.68 per share [18] - The company closed the quarter with approximately $2 billion in cash and cash equivalents, indicating strong financial flexibility [18] Business Line Data and Key Metrics Changes - The rollout of the Dexcom G7 15-day system has received positive feedback, enhancing customer experience and potentially increasing market share [6][12] - The company is focusing on improving customer experience through new digital support systems and AI integration [7][8] - The early access launch of Dexcom Smart Basal aims to improve outcomes for Type 2 diabetes management [8] Market Data and Key Metrics Changes - The international business showed strength, particularly in Germany, the United Kingdom, and France, with France being one of the fastest-growing markets due to Type 2 access expansion [16] - The company anticipates that international market opportunities could surpass those in the U.S. over time [11] Company Strategy and Development Direction - The company aims to be the premier glucose sensing solution, focusing on sensor accuracy, reliability, and connectivity [6] - Strategic priorities include enhancing customer experience, expanding international market share, and driving growth through product innovation [10][11] - The company plans to introduce new products in 2026, including Stelo and a new CGM system for international markets [11] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth potential in metabolic health management and the impact of upcoming Medicare coverage for Type 2 non-insulin users [24][26] - The company expects total revenue for 2026 to be in the range of $5.16 billion to $5.25 billion, reflecting growth of 11%-13% [19][20] - Management highlighted the importance of maintaining gross margin improvements and operational efficiencies while investing in new facilities [20][47] Other Important Information - The company has surpassed $1 billion in free cash flow for the first time in 2025 [19] - An Investor Day is planned for May 2026 to provide further details on the company's outlook [13] Q&A Session Summary Question: Discussion on the company's glucose sensing journey and market potential - Management believes the company is in the early stages of addressing metabolic health issues, with significant growth opportunities in Type 2 coverage expected in the next 12-24 months [24][26] Question: Inquiry about CMS coverage for Type 2 non-insulin users - Management is optimistic about upcoming CMS coverage decisions and is preparing for potential impacts on market access [30][33] Question: Impact of the 15-day product rollout on margins and new markets - The 15-day product is expected to contribute to margins over time, with significant opportunities for international expansion [36][39] Question: Discussion on operating expenses and investments - Increased operating expenses are primarily due to investments in the new Ireland manufacturing facility, which will enhance future production capabilities [46][47] Question: Utilization rates among different user segments - Utilization rates remain stable across various user segments, with high engagement expected to drive further growth [51][52] Question: Revenue outlook and new patient dynamics for 2026 - Revenue growth will depend on patient retention, utilization, and pricing strategies, with a focus on maintaining a stable user base [56][60] Question: Stability of the U.S. sensor uptake trends - Management noted improvements in sensor deployment and stable user retention, contributing to positive sell-through trends [64][66] Question: Pricing dynamics related to Medicare coverage - Pricing strategies will be influenced by competitive bidding processes, with expectations for stable pricing amidst increased volume [72][74] Question: International market growth strategies - The company plans to deepen its presence in existing markets and expand into new regions, with a focus on generating evidence to support market access [80][82]

Financial Data and Key Metrics Changes - The company reported worldwide revenue of $1.21 billion for Q3 2025, a 22% increase compared to $994 million in Q3 2024, with organic revenue growth of 20% [20][21] - U.S. revenue reached $852 million, up 21% from $702 million in the same quarter last year [20][21] - Gross profit was $741.3 million, representing 61.3% of revenue, down from 63.0% in Q3 2024 [22] - Operating income was $272.9 million, or 22.6% of revenue, compared to $212.0 million, or 21.3% in Q3 2024 [24] - Net income for Q3 was $242.5 million, or $0.61 per share, marking the highest quarterly earnings per share in the company's history [24] Business Line Data and Key Metrics Changes - The company experienced strong growth in Type 2 diabetes segments, with new customer starts increasingly coming from this population due to expanded coverage [8][20] - The introduction of Dexcom Smart Basal aims to enhance the management of basal insulin for Type 2 customers, addressing their specific needs [11][12] - Stelo surpassed $100 million in revenue within its first year, indicating strong market acceptance and growth potential [13][14] Market Data and Key Metrics Changes - International revenue grew 22% to $357.4 million, with organic growth of 18%, marking the third consecutive quarter of accelerating international growth [21] - France and Canada were highlighted as strong markets, with France showing consistent growth due to new coverage [21] Company Strategy and Development Direction - The company is focused on expanding coverage for Type 2 diabetes patients, aiming to secure access for the entire population of over 25 million Americans [9][10] - The launch of the G7 15 Day system is anticipated to enhance the company's product offerings and market position [14][15] - The company is committed to improving customer experience through new digital platforms and ongoing software updates [16][18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth trajectory, emphasizing the importance of expanding access to CGM for Type 2 diabetes patients [8][9] - The company acknowledged challenges related to sensor deployment but indicated improvements have been made, leading to a positive outlook for Q4 and beyond [34][35] - Management expects to return to record levels of new patient starts in 2026, driven by existing coverage and potential new coverage opportunities [77] Other Important Information - The company raised its revenue guidance for 2025 to a range of $4.630 billion to $4.650 billion, reflecting approximately 15% growth for the year [25] - Operating expenses increased to $468.4 million in Q3 2025, up from $413.9 million in Q3 2024, as the company continues to invest in R&D [24] Q&A Session Summary Question: Insights on 2026 growth estimates - Management refrained from providing specific guidance for 2026 but indicated a positive outlook based on current coverage and access to CGM [30][31] Question: G7 performance and deployment issues - Management confirmed that deployment challenges have been addressed, and they expect improvements in new starts and prescribing patterns moving forward [34][35] Question: Growth in new patient segments - The company noted strong performance across all Type 2 markets, including intensive and non-insulin users, and is actively exploring marketing strategies to drive uptake [40][41] Question: Expanded coverage potential for 2026 - Management stated that the base case for guidance includes current coverage, with potential for expanded coverage being a positive but not guaranteed factor [44][45] Question: 15 Day sensor launch and revenue contribution - The company is excited about the upcoming broader launch of the 15 Day sensor, with expectations for it to contribute to revenue growth in 2026 [52][53] Question: Gross margin and scrap rate issues - Management indicated that scrap and freight issues have impacted margins but expect improvements as they transition back to more cost-efficient shipping methods [70][72]

Financial Data and Key Metrics Changes - The company is guiding for 14% to 15% top-line growth for the year, with an expectation of about 200 basis points of operating margin leverage [14][30] - The company aims to execute on its 2025 commitments after not meeting them last year, emphasizing the importance of achieving revenue and operating margin targets [10][30] Business Line Data and Key Metrics Changes - The company reported a strong performance in the continuous glucose monitoring (CGM) segment, with a focus on expanding coverage and access globally [11][15] - The Stelo product has generated $100 million in revenue within its first twelve months, indicating strong market acceptance [41] Market Data and Key Metrics Changes - The company is seeing increased coverage for CGM, with more people having access than currently using the technology, suggesting significant growth potential [7][15] - International markets are expected to contribute to growth, with a tiered pricing model allowing for incremental revenue from new markets [36] Company Strategy and Development Direction - The company is focused on building a metabolic health platform, with continued emphasis on diabetes management while exploring broader applications [8] - Strategic priorities include expanding international presence, enhancing commercial infrastructure, and preparing for increased coverage in type two diabetes [12][13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving strong double-digit growth in the foreseeable future, driven by expanding healthcare coverage and market opportunities [15] - The management team is actively working on a long-range plan (LRP) to provide clearer guidance to investors, expected to be released soon [16][18] Other Important Information - The company addressed concerns regarding the reliability and accuracy of its G7 product, stating improvements have been made and deployment challenges have been resolved [21][22] - The upcoming launch of a 15-day sensor is expected to enhance product offerings and customer experience [26][29] Q&A Session Summary Question: What are the strategic priorities for the next 12 to 24 months? - The company emphasized executing on 2025 commitments, expanding CGM coverage, and scaling operations [10][11] Question: How does the company view growth moving forward? - Management sees strong double-digit growth potential based on existing and upcoming healthcare coverage [15] Question: What is the outlook for international markets? - The company plans to push harder into international markets with a tiered pricing model and expects significant growth opportunities [36] Question: How is the company addressing recent concerns about G7 reliability? - Management stated that improvements have been made and that they are confident in the product's performance [21][22] Question: What is the expected impact of the 15-day sensor launch? - The company is confident in the quality of the 15-day sensor and is preparing for a smooth transition for users [26][29] Question: What is the timeline for the randomized controlled trial (RCT) for type two diabetes? - The RCT is expected to read out in the first part of next year, with results anticipated to support access submissions globally [52][53] Question: How does the company view competitive threats from Abbott's upcoming products? - Management believes that their existing products, particularly the G7, provide critical safety features that will maintain competitive advantage [71][72]

Financial Data and Key Metrics Changes - The company reported worldwide revenue of $1,036 million for Q1 2025, a 12% increase compared to $921 million in Q1 2024, with organic revenue growth of 14% [18] - U.S. revenue totaled $751 million, up 15% from $653 million in Q1 2024, driven by strong new customer demand [19] - International revenue grew 7% to $286 million, with organic growth of 12% [21] - Gross profit was $596.2 million, representing 57.5% of revenue, down from 61.8% in Q1 2024 [23] - Operating income was $143.1 million, or 13.8% of revenue, compared to $140.2 million in the same quarter of 2024 [24] - Adjusted EBITDA was $230.4 million, or 22.2% of revenue, compared to $220.9 million, or 24% of revenue in Q1 2024 [25] - Net income for Q1 was $127.7 million, or $0.32 per share [26] Business Line Data and Key Metrics Changes - The company experienced record levels of new customer demand, particularly from the Type 2 non-insulin using population [9][10] - The introduction of Stello, the first over-the-counter CGM, and broader access in the Type 2 market contributed to increased customer starts [10][12] - The company launched a 180-day data look-back feature for the Stello app, enhancing customer experience [13] Market Data and Key Metrics Changes - The company secured access at two of the three largest PBMs for diabetes patients, which is expected to cover nearly six million people with Type 2 diabetes by the end of the year [10][11] - International business showed strength in Japan and France, with continued growth in the Type 2 landscape [22] Company Strategy and Development Direction - The company is focused on expanding coverage for Type 2 diabetes patients and enhancing customer experience through technology and software updates [10][12] - The introduction of the 15-day G7 system is expected to set a new industry standard for sensor accuracy and wear time [16] - The company is committed to addressing FDA concerns following a warning letter and is working on corrective actions [15][102] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating supply dynamics and maintaining customer care during the transition period [6][19] - The company reaffirmed its revenue guidance of $4.6 billion for the year, representing 14% growth, while adjusting gross margin guidance to approximately 62% [27][29] - Management is optimistic about the potential for broader Type 2 coverage and the positive reception of CGM technology in the healthcare landscape [10][110] Other Important Information - The company announced a $750 million share repurchase program, reflecting strong cash flow and financial position [26] - Management highlighted the importance of evidence-based data in driving changes to standards of care and expanding access globally [11] Q&A Session Summary Question: Did supply have any impact on the revenue growth? - Management indicated that supply dynamics were normalized by the end of the quarter, and strong new patient performance was observed despite previous challenges [35] Question: Why is full-year guidance unchanged despite strong Q1 growth? - Management stated that it is prudent to wait and see how the year unfolds before adjusting guidance, emphasizing the importance of a full-year perspective [42] Question: What are the trends in Type 2 patient utilization and reorder rates? - Management reported good retention and utilization rates among Type 2 patients, particularly those with reimbursement coverage [50] Question: How exposed is the company to a potential recession? - Management believes the company is well-positioned to weather economic downturns due to the cost-saving benefits of its products [58][60] Question: What is the status of the FDA warning letter? - Management confirmed that the warning letter does not restrict new submissions or approvals and that they are making progress in addressing FDA concerns [102] Question: What is the timeline for the RCT data readout for Type 2 non-insulin users? - Management anticipates finishing enrollment in the first half of the year, with initial data readout expected late this year or early next year [112]